Short Telomeres Drive Clonal Blood Cell Takeover in Aging and Leukemia

Clonal hematopoiesis (CH)—the age-related dominance of blood production by stem cells carrying somatic mutations—is a known risk factor for blood cancers and cardiovascular disease. Splicing factor mutations (in genes such as SF3B1, SRSF2, and U2AF1) are common in myeloid malignancies and CH, yet why they confer such strong age-dependent clonal advantages has remained obscure. This landmark study in Nature Genetics proposes that telomere attrition is a key missing piece of that puzzle.

Using data from 454,098 UK Biobank participants, the authors performed large-scale association analyses between genetically predicted leukocyte telomere length (LTL) and the presence of specific CH mutation subtypes detected by whole-exome or whole-genome sequencing. Crucially, they used polygenic scores for telomere length—capturing inherited telomere biology rather than environmentally confounded measured telomere length—to establish more causal relationships. While most CH subtypes (e.g., DNMT3A, TET2) showed no strong association with telomere length, splicing-factor-mutant CH was significantly enriched in individuals with genetically shorter telomeres. Mutations in PPM1D (a DNA damage checkpoint regulator) and the TERT promoter showed similar enrichment, suggesting a shared biology around telomere stress responses.

The mechanistic interpretation is compelling: as HSCs accumulate replication-driven telomere shortening over decades, those approaching critically short telomeres face senescence or apoptosis. Splicing factor mutations appear to 'rescue' HSCs from this fate—perhaps by altering RNA splicing of genes involved in the DNA damage response or telomere maintenance—granting them a proliferative advantage over non-mutant neighbors. This reframes telomere attrition not as a passive aging process but as an active clonal selection pressure that determines which mutations rise to dominance in the aging hematopoietic system.

The findings also illuminate leukemogenesis: splicing-factor-driven myeloid malignancies (such as myelodysplastic syndromes) are predominantly diseases of the elderly, and this study suggests their age-dependence is partly explained by the time required for sufficient telomere erosion to create the selective environment in which these mutations thrive. PPM1D mutations, which dampen p53-mediated responses to DNA damage including telomere dysfunction, fit logically into this model. TERT promoter mutations, which reactivate telomerase, represent a parallel strategy—gaining advantage by directly extending telomeres rather than tolerating their shortness.

This work opens potential therapeutic avenues: interventions targeting telomere biology or splicing-factor-dependent pathways in HSCs may help prevent or treat splicing-factor-mutant CH and associated malignancies. The study also raises the possibility that maintaining telomere length through lifestyle or pharmacological means could reduce the selective pressure that favors dangerous clonal expansions.